Taysha Gene Therapies CEO RA Session's 2021 pay slips 3% to $4.6M
Taysha Gene Therapies reports 2021 executive compensation
By ExecPay News
Published: April 28, 2022
Taysha Gene Therapies reported fiscal year 2021 executive compensation information on April 28, 2022.
In 2021, three executives at Taysha Gene Therapies received on average a compensation package of $2.9M, a 39% decrease compared to previous year.
Average pay of disclosed executives at Taysha Gene Therapies
RA Session II, Chief Executive Officer, received $4.6M in total, which decreased by 3% compared to 2020. 88% of Session's compensation, or $4M, was in option awards. Session also received $543K in salary and $150 in other compensation.
Suyash Prasad, M.B.B.S, F.F.P.M, Chief Medical Officer, received a compensation package of $2.2M, which decreased by 44% compared to previous year. 72% of the compensation package, or $1.6M, was in option awards.
Kamran Alam, Chief Financial Officer, earned $1.8M in 2021, a 67% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on April 28, 2022.